An FDA committee has given an overwhelming recommendation to new inhaled insulin treatment Afrezza. MannKind Corporation has spent years and many millions of dollars in developing the novel ...

“The availability of Afrezza has the potential to help so many people in India living with diabetes in improving glycemic control via a non-injectable and convenient delivery of inhaled insulin ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

Medscape Medical News, June 27, 2024 ADA 2024 Inhaled Insulin Plus Degludec an Option for Type 1 Diabetes Use of premeal Afrezza insulin plus long-acting degludec insulin was non-inferior to ...

Cipla Limited on Wednesday announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

“The availability of Afrezza has the potential to help so many people in India living with diabetes in improving glycemic control via a non-injectable and convenient delivery of inhaled insulin,” said ...